These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 20838435)
1. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. Cooper LA; Gutman DA; Long Q; Johnson BA; Cholleti SR; Kurc T; Saltz JH; Brat DJ; Moreno CS PLoS One; 2010 Sep; 5(9):e12548. PubMed ID: 20838435 [TBL] [Abstract][Full Text] [Related]
2. Phospholipase C Beta 1: a Candidate Signature Gene for Proneural Subtype High-Grade Glioma. Lu G; Chang JT; Liu Z; Chen Y; Li M; Zhu JJ Mol Neurobiol; 2016 Nov; 53(9):6511-6525. PubMed ID: 26614510 [TBL] [Abstract][Full Text] [Related]
3. Co-expression of mitosis-regulating genes contributes to malignant progression and prognosis in oligodendrogliomas. Liu Y; Hu H; Zhang C; Wang H; Zhang W; Wang Z; Li M; Zhang W; Zhou D; Jiang T Oncotarget; 2015 Nov; 6(35):38257-69. PubMed ID: 26468983 [TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor beta induced (TGFBI) is a potential signature gene for mesenchymal subtype high-grade glioma. Pan YB; Zhang CH; Wang SQ; Ai PH; Chen K; Zhu L; Sun ZL; Feng DF J Neurooncol; 2018 Apr; 137(2):395-407. PubMed ID: 29294230 [TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome. Kiviniemi A; Gardberg M; Kivinen K; Posti JP; Vuorinen V; Sipilä J; Rahi M; Sankinen M; Minn H Oncotarget; 2017 Jul; 8(30):49123-49132. PubMed ID: 28467778 [TBL] [Abstract][Full Text] [Related]
6. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas. Paul Y; Mondal B; Patil V; Somasundaram K Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842 [TBL] [Abstract][Full Text] [Related]
7. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference. Zhang C; Li J; Wang H; Song SW Oncotarget; 2016 Nov; 7(45):73971-73983. PubMed ID: 27738332 [TBL] [Abstract][Full Text] [Related]
8. Molecular subtypes of glioblastoma are relevant to lower grade glioma. Guan X; Vengoechea J; Zheng S; Sloan AE; Chen Y; Brat DJ; O'Neill BP; de Groot J; Yust-Katz S; Yung WK; Cohen ML; Aldape KD; Rosenfeld S; Verhaak RG; Barnholtz-Sloan JS PLoS One; 2014; 9(3):e91216. PubMed ID: 24614622 [TBL] [Abstract][Full Text] [Related]
9. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients. Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941 [TBL] [Abstract][Full Text] [Related]
10. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas. Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009 [TBL] [Abstract][Full Text] [Related]
11. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179 [TBL] [Abstract][Full Text] [Related]
13. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864 [TBL] [Abstract][Full Text] [Related]
14. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma. Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920 [TBL] [Abstract][Full Text] [Related]
15. Higher YAP1 Levels Are Associated With Shorter Survival of Patients With Low Grade Astrocytoma. Dicke J; Hero L; Kuhl S; Görtz L; Goldbrunner R; Timmer M Anticancer Res; 2024 Jul; 44(7):3005-3011. PubMed ID: 38925840 [TBL] [Abstract][Full Text] [Related]
16. Gene expression analyses of grade II gliomas and identification of rPTPbeta/zeta as a candidate oligodendroglioma marker. Hägerstrand D; Smits A; Eriksson A; Sigurdardottir S; Olofsson T; Hartman M; Nistér M; Kalimo H; Ostman A Neuro Oncol; 2008 Feb; 10(1):2-9. PubMed ID: 18003890 [TBL] [Abstract][Full Text] [Related]
17. Identification of Periostin as a Potential Biomarker in Gliomas by Database Mining. Faried A; Hermanto Y; Tjahjono FP; Valentino A; Arifin MZ World Neurosurg; 2020 Mar; 135():e137-e163. PubMed ID: 31785437 [TBL] [Abstract][Full Text] [Related]
18. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas. Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L Front Immunol; 2020; 11():603341. PubMed ID: 33363544 [TBL] [Abstract][Full Text] [Related]
19. Coexpression network analysis identifies transcriptional modules related to proastrocytic differentiation and sprouty signaling in glioma. Ivliev AE; 't Hoen PA; Sergeeva MG Cancer Res; 2010 Dec; 70(24):10060-70. PubMed ID: 21159630 [TBL] [Abstract][Full Text] [Related]
20. Integrated Transcriptomic Analysis of Necrosis-related Gene in Diffuse Gliomas. Wang J; Ma J J Neurol Surg A Cent Eur Neurosurg; 2019 Jul; 80(4):240-249. PubMed ID: 30934097 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]